title: The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
abstract: Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have been shown previously. The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD. In this randomised double-blinded placebo-controlled clinical trial, fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and physical activity recommendations. resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P0·05). There were no significant changes in blood pressure, insulin resistance markers and TAG in either group (P>0·05). Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.
authors.affiliation: 1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology,National Nutrition and Food Technology Research Institute,Shahid Beheshti University of Medical Sciences,Tehran 19395-4741,Iran.
authors.forename: Forouzan
authors.initials: F
authors.lastname: Faghihzadeh
authors.affiliation: 2Integrative Functional Gastroenterology Research Center,Isfahan University of Medical Sciences,Isfahan 81744,Iran.
authors.forename: Payman
authors.initials: P
authors.lastname: Adibi
authors.affiliation: 1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology,National Nutrition and Food Technology Research Institute,Shahid Beheshti University of Medical Sciences,Tehran 19395-4741,Iran.
authors.forename: Azita
authors.initials: A
authors.lastname: Hekmatdoost
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000378:metabolism*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005234:Fatty Liver / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D000077185:Resveratrol; D012307:Risk Factors; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D015415:Biomarkers; D010936:Plant Extracts; D013267:Stilbenes; D014280:Triglycerides; D000410:Alanine Transaminase; D000077185:Resveratrol
keywords: ALT alanine aminotransferase; Clinical trials; Fatty liver; Inflammation; NAFLD non-alcoholic fatty liver disease; Non-alcoholic fatty liver disease; Resveratrol; SBP systolic blood pressure